The article "Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support" describes a case study of a patient with metastatic pancreatic neuroendocrine carcinoma (pNET) that was resistant to standard chemotherapy treatments. The patient underwent liquid biopsy testing, which identified genomic mutations in the tumor DNA that were potentially targetable by available drugs. A computational decision support tool, Genomate, was then used to analyze the genomic data and identify personalized treatment options based on the patient's individual molecular profile.

Key Takeaways:

• The article describes a case study of a patient with metastatic pancreatic neuroendocrine carcinoma (pNET) that was resistant to standard chemotherapy treatments.
• Liquid biopsy testing identified genomic mutations in the tumor DNA that were potentially targetable by available drugs.
• A computational decision support tool, Genomate, was used to analyze the genomic data and identify personalized treatment options based on the patient's individual molecular profile.
• The patient was treated with a combination of everolimus, a drug that targets the mTOR pathway, and sunitinib, a drug that targets multiple tyrosine kinase receptors.
• The patient showed a partial response to the treatment, with a reduction in tumor size and improvement in symptoms.
• This case study demonstrates the potential of liquid biopsy testing and computational decision support tools like Genomate to identify personalized treatment options for patients with metastatic pNET, and highlights the importance of a precision medicine approach to cancer treatment.

‍

Read the entire article here.

‍Szkukalek J, Dóczi R, Dirner A, Boldizsár Á, Varga Á, Déri J, Lakatos D, Tihanyi D, Vodicska B, Schwáb R, Pajkos G, Várkondi E, Vályi-Nagy I, Valtinyi D, Nagy Z, Peták I.
Diagnostics (Basel). 2021 Oct 7;11(10):1850. doi: 10.3390/diagnostics11101850. PMID: 34679548; PMCID: PMC8534772.

‍